medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-3-22(397)-37-42medalphabet-1207Research ArticleСтатьиВзаимосвязь профилей антинуклеарных антител и цитокинов при системной красной волчанкеRelationship of profiles of antinuclear antibodies and cytokines in systemic lupus erythematosusАлександроваЕ. Н.AleksandrovaE. N.

д. м. н., зав. лабораторией клинической иммунологии

г. Москва

Moscow

НовиковА. А.NovikovA. A.

д. б. н., вед. н. с. лаборатории клинической иммунологии

г. Москва

Moscow

ВерижниковаЖ. Г.VerizhnikovaZh. G.

врач КЛД лаборатории иммунодиагностики

г. Москва

Moscow

ПанафидинаТ. А.PanafidinaT. A.

к. м. н., н. с. лаборатории системных ревматических заболеваний

г. Москва

Moscow

ЛукинаГ. В. LukinaG. V.

д. м. н., проф., зав. отделом ревматологии; вед. н. с. лаборатории мониторинга безопасности антиревматических препаратов

г. Москва

Moscow

ГБУЗ г. Москвы «Московский клинический научно-практический центр имени А. С. Логинова» Департамента здравоохранения г. МосквыРоссияA. S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare DepartmentRussian FederationФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»РоссияV. A. Nasonova Research Institute of RheumatologyRussian FederationГБУЗ г. Москвы «Московский клинический научно-практический центр имени А. С. Логинова» Департамента здравоохранения г. Москвы; ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»РоссияA. S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department; V. A. Nasonova Research Institute of RheumatologyRussian Federation201922112019322Современная лаборатория3742Copyright © Александрова Е.Н., Новиков А.А., Верижникова Ж.Г., Панафидина Т.А., Лукина Г.В., 20192019Александрова Е.Н., Новиков А.А., Верижникова Ж.Г., Панафидина Т.А., Лукина Г.В.Aleksandrova E.N., Novikov A.A., Verizhnikova Z.G., Panafidina T.A., Lukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1207

Системная красная волчанка (СКВ) — системное аутоиммунное заболевание, характеризующееся патологической активацией врожденного и приобретенного иммунного ответа, образованием антинуклеарных антител (АНА) и дисрегуляцией продукции цитокинов. Цель работы: изучить взаимосвязь профилей АНА и цитокинов у больных СКВ при использовании мультиплексного иммунного анализа (МИА) данных биомаркеров. Обследовано 94 больных СКВ (критерии диагноза SLICC, 2012) и 28 здоровых доноров. Профили АНА и цитокинов в сыворотке крови определяли на основе суспензионной микрочиповой технологии хМАР. При СКВ наиболее часто выявлялись антитела к дсДНК (52,1 %), нуклеосомам (54,3 %) и SS-A/Ro (37,2 %), реже к Sm (28,7 %), RibP (14,9 %), РНП-70 (13,8 %) и SS-B/La (11,7 %). Активность заболевания (SLEDAI-2K) положительно коррелировала с концентрацией антител к дсДНК (r = 0,6), нуклеосомам (r = 0,7), Sm (r = 0,4) и RibP (r = 0,3) (p < 0,05). В сыворотках больных СКВ идентифицировано повышение уровней IL-4, -6, -8, -12, GM-CSF, MCP-1, MIP-1β, RANTES и снижение содержания IL-1β, IL-1ra, IL-2, IL-9, IL-10, эотаксина, G-CSF, IFN-γ, MIP-1α, TNF-α, FGF, PDGF-BB, VEGF по сравнению с донорами (р < 0,05). Увеличение концентрации IP-10 и MCP-1 ассоцировалось с высокой активностью заболевания (r = 0,4; r = 0,3; р < 0,05), гиперпродукцией антител к дсДНК (r = 0,3), нуклеосомам (r = 0,5), Sm (r = 0,5), SS-B/La (r = 0,3), RibP (r = 0,4) (p < 0,05) и антител к Sm (r = 0,3), SS-B/La (r = 0,3), RibP (r = 0,3) (p < 0,05) соответственно.

Вывод: образование АНА и высокая активность СКВ ассоциируются с гиперэкспрессией хемокинов IP-10 и MCP-1, индуцируемых IFN.

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by pathological activation of the innate and acquired immune response, the formation of antinuclear antibodies (ANA), and dysregulation of cytokine production. Objective: to study the relationship of ANA and cytokine profiles in patients with SLE using multiplex immune analysis (MIA) of these biomarkers. We examined 94 patients with SLE (SLICC diagnosis criteria, 2012) and 28 healthy donors. Profiles of ANA and cytokines in blood serum were determined on the basis of suspension microarray technology xMAP. In SLE, antibodies to dsDNA (52.1 %), nucleosomes (54.3 %) and SS-A/Ro (37.2 %), less often to Sm (28.7 %), RibP (14, 9 %), RNP-70 (13.8 %) and SS-B/La (11.7 %). Disease activity (SLEDAI-2K) positively correlated with the concentration of antibodies to dsDNA (r = 0.6), nucleosomes (r = 0.7), Sm (r = 0.4) and RibP (r = 0.3) (p < 0.05). In the sera of patients with SLE, an increase in the levels of IL-4, -6, -8, -12, GM-CSF, MCP-1, MIP-1β, RANTES and a decrease in the content of IL-1β, IL-1ra, IL-2, IL-9, IL-10, eotaxin, G-CSF, IFN-γ, MIP-1α, TNF-α, FGF, PDGF-BB, VEGF compared to donors (p < 0.05). An increase in the concentration of IP-10 and MCP-1 was associated with high disease activity (r = 0.4; r = 0.3; p < 0.05), hyperproduction of antibodies to dsDNA (r = 0.3), nucleosomes (r = 0.5), Sm (r = 0.5), SS-B/La (r = 0.3), RibP (r = 0.4) (p < 0.05) and antibodies to Sm (r = 0.3), SS-B/La (r = 0.3), RibP (r = 0.3) (p < 0.05), respectively.

Conclusion: the formation of ANA and high activity of SLE are associated with the overexpression of chemokines IP-10 and MCP-1 induced by IFN. 

системная красная волчанкаантинуклеарные антителацитокиныактивность заболеваниямультиплексный иммунный анализsystemic lupus erythematosusantinuclear antibodiescytokinesdisease activitymultiplex immune assayReferencesСоловьев С. К., Клюквина Н. Г. Системная красная волчанка. В книге: Насонов Е. Л., редактор. Ревматология: Клинические рекомендации. 2-е изд. М.: ГЭОТАР-Медиа; 2010. С. 429–81.Соловьев С. К., Клюквина Н. Г. Системная красная волчанка. В книге: Насонов Е. Л., редактор. Ревматология: Клинические рекомендации. 2-е изд. М.: ГЭОТАР-Медиа; 2010. С. 429–81.Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculosceletal Dis. 2013; 5: 210–33.Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculosceletal Dis. 2013; 5: 210–33.Podolska MJ, Biermann MH, Maueröder C, Hahn J, Herrmann M. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015; 8: 161–71.Podolska MJ, Biermann MH, Maueröder C, Hahn J, Herrmann M. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015; 8: 161–71.Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford). 2017; 56 (suppl. 1): i32—i45.Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford). 2017; 56 (suppl. 1): i32—i45.Zharkova O, Celhar T, Cravens PD, Satterthwaite AB, Fairhurst AM, Davis LS. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology (Oxford). 2017; 56 (suppl. 1): i55—i66.Zharkova O, Celhar T, Cravens PD, Satterthwaite AB, Fairhurst AM, Davis LS. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology (Oxford). 2017; 56 (suppl. 1): i55—i66.Александрова Е. Н., Новиков А. А., Насонов Е. Л. Лабораторная диагностика ревматических заболеваний. В кн.: Насонов Е. Л., ред. Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2017. С. 300–18.Александрова Е. Н., Новиков А. А., Насонов Е. Л. Лабораторная диагностика ревматических заболеваний. В кн.: Насонов Е. Л., ред. Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2017. С. 300–18.Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73 (1): 17–23.Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73 (1): 17–23.Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64 (8): 2677–86.Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64 (8): 2677–86.Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014; 2014: 315179.Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014; 2014: 315179.Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthr Rheum. 2007; 56: 1736–44.Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthr Rheum. 2007; 56: 1736–44.Dorner T. Deciphering the role of NETs and networks in SLE. Nat Rev Rheumatol. 2012; 8: 68–70.Dorner T. Deciphering the role of NETs and networks in SLE. Nat Rev Rheumatol. 2012; 8: 68–70.Pisetsky DS. Antinuclear antibody testing — misunderstood or misbegotten? Nat Rev Rheumatol. 2017; 13 (8): 495–502.Pisetsky DS. Antinuclear antibody testing — misunderstood or misbegotten? Nat Rev Rheumatol. 2017; 13 (8): 495–502.Yap DI, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosus — from bench to bedside. Nephrology. 2013; 18: 243–55.Yap DI, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosus — from bench to bedside. Nephrology. 2013; 18: 243–55.Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D’Elios MM, Prisco D, Emmi L. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014; 5 (2): 33–45.Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D’Elios MM, Prisco D, Emmi L. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014; 5 (2): 33–45.Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009; 60: 3098–107.Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009; 60: 3098–107.Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Ryel J et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008; 58: 2453–9.Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Ryel J et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008; 58: 2453–9.Chun HY, Chung JW, Kim HA, Yun J, Jeon J, Ye Y et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27: 461–6.Chun HY, Chung JW, Kim HA, Yun J, Jeon J, Ye Y et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27: 461–6.Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004; 50: 2048–65.Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004; 50: 2048–65.Li QZ, Zhou J, Lian Y, Zhang B, Branch VK, Carr-Johnson F et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes Clin Exp Immunol. 2010; 159 (3): 281–91.Li QZ, Zhou J, Lian Y, Zhang B, Branch VK, Carr-Johnson F et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes Clin Exp Immunol. 2010; 159 (3): 281–91.Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016; 74: 182–193.Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016; 74: 182–193.Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen microarray for high-throughput autoantibody profiling in Systemic Lupus Erythematosus. Genomics Proteomics Bioinformatics. 2015; 13 (4): 210–8.Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen microarray for high-throughput autoantibody profiling in Systemic Lupus Erythematosus. Genomics Proteomics Bioinformatics. 2015; 13 (4): 210–8.Wang L, Mohan C, Li QZ. Arraying autoantibodies in SLE — Lessons Learned. Curr Mol Med. 2015; 15 (5): 456–61.Wang L, Mohan C, Li QZ. Arraying autoantibodies in SLE — Lessons Learned. Curr Mol Med. 2015; 15 (5): 456–61.Adhya Z, Borozdenkova S, Karim MY. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol Dial Transplant. 2011; 26 (10): 3273–80.Adhya Z, Borozdenkova S, Karim MY. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol Dial Transplant. 2011; 26 (10): 3273–80.Pacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodríguez Y et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017; 15 (1): 239.Pacheco Y, Barahona-Correa J, Monsalve DM, Acosta-Ampudia Y, Rojas M, Rodríguez Y et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017; 15 (1): 239.Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E et al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018; 20 (1): 173.Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E et al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018; 20 (1): 173.Bauer J, Baechler E, Petri M, Batliwalla F, Crawford D, Ortmann W et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006; 3 (12): e 491.Bauer J, Baechler E, Petri M, Batliwalla F, Crawford D, Ortmann W et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006; 3 (12): e 491.Kirou K, Lee C, George S, Louca K, Peterson M, Crow M. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52: 1491–1503.Kirou K, Lee C, George S, Louca K, Peterson M, Crow M. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52: 1491–1503.

The authors declare that there are no conflicts of interest present.